Overall, 6-P might functioned as an anti-tumor drug to inhibit pancreatic cancer cell proliferation and migration in vivo and in vitro by targeting EGFR, inducing EGFR degradation through decreasing the protein stability of EGFR and enhancing the ubiquitin-mediated proteasome-dependent degradation. This evidence concerns the gene EGFR and familial pancreatic carcinoma.